ArticleBMC infectious diseases2026
Incidence and healthcare costs of symptomatic dengue in an urban, city-wide cohort in South India.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGaps in India’s routine dengue surveillance have led to an underestimation of its actual burden and could adversely affect funding for preventive public health measures. In this study, we report the incidence of symptomatic dengue and the associated direct medical costs in a large urban population-based cohort in Vellore, Tamil Nadu.
methodsSurveillance for febrile illnesses was conducted in 30 urban wards in Vellore as part of the Vellore Typhoid Vaccine Impact Trial. Participants seeking healthcare for febrile illnesses called the trial helpline, triggering active surveillance until fever defervescence. Febrile episodes lasting ≥ 3 days were diagnosed as dengue based on either laboratory tests or a physician-assigned diagnosis.
resultsFrom May 2023 to January 2025, 74,587 participants aged 1–30 years contributed 124,018.4 person-years (PYs) of follow-up. We identified 188 laboratory-confirmed and 107 physician-assigned diagnoses of dengue. From May 2023 to April 2024, the incidence of laboratory-confirmed dengue was 150.3 per 100,000 PYs (95% confidence interval [CI]: 124.4–181.7), and 205.2 per 100,000 PYs (95% CI: 174.4–241.3) for all dengue cases. The median direct medical cost for laboratory-confirmed dengue treated as outpatients was Indian Rupees (INR) 4,357 (interquartile range [IQR]: 2,432–7,204), and INR 16,827 (IQR: 9,556–26,348) for those who were hospitalised.
conclusionsThe incidence of dengue and its associated treatment costs were high in this urban setting. Strengthening routine disease surveillance with enhanced diagnostic testing and systematically collected data from the private sector will provide better estimates of the dengue burden in India and inform policy decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.